Journal
JOURNAL OF CLINICAL NEUROSCIENCE
Volume 16, Issue 2, Pages 246-252Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2008.01.020
Keywords
Dopamine transporter; Parkinsonism; SPECT; 123I-ioflupane
Categories
Ask authors/readers for more resources
To assess the impact of I-123 ioflupane single photon emission computed tomography (SPECT) imaging on classifying patients with striatal dopaminergic deficits. Sixty-one patients with an initial diagnosis of parkinsonism or uncertain tremor disorder were screened and followed-up for one year. All patients were re-examined by two neurologists at our centre and were classified as having neurodegenerative or non-neurodegenerative disorders. Patients underwent I-123 ioflupane SPECT imaging. SPECT studies were blindly evaluated and classified as normal or abnormal (indicative of neurodegenerative disorders). The overall agreement of the SPECT imaging results with the initial classification was 65.6% (kappa = 0.229, p = 0.074) but was 90.2% (kappa = 0.782, p < 0.001) with the classification of the neurologists at our centre. I-123 ioflupane SPECT imaging is a valuable method in the evaluation of patients presenting clinically with uncertain parkinsonian syndromes or for whom diagnostic doubt exists. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available